Israel Englander Graphite Bio, Inc. Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$2.24 - $2.66 $121,504 - $144,286	54,243 Added 149.33%	90,568 $237,000
Q2 2023 Aug 14, 2023	SELL	$2.47 - $3.38 $91,160 - $124,745	-36,907 Reduced 50.4%	36,325 $94,000
Q1 2023 May 15, 2023	SELL	$1.85 - $3.21 $111,207 - $192,959	-60,112 Reduced 45.08%	73,232 $179,000
Q4 2022 Feb 14, 2023	SELL	$2.82 - $3.59 $612,856 - $780,196	-217,325 Reduced 61.97%	133,344 $443,000
Q3 2022 Nov 14, 2022	SELL	$2.82 - $4.24 $495,138 - $744,463	-175,581 Reduced 33.36%	350,669 $1.11 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.